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To my Family
Abstract
Studies have shown that there could be an association between dietary calcium and
cancer, and more specifically it has been suggested that serum calcium is involved in
the etiology of cancers of the prostate. In order to explore this association we per-
formed epidemiological studies of the association between pre-diagnostic serum cal-
cium and prostate cancer incidence and survival. We also studied temporal trends in
the survival in Hodgkin’s Lymphoma in order to evaluate the advances in treatment
routines.
In our relative survival analysis of Hodgkin’s Lymphoma we could see that those diag-
nosed in the later periods of time had considerably higher 1-, 5- and 10-year survival.
This improvement in survival was especially prominent for those aged 51-65 years.
Despite this, the long-term survival is still low in the older age groups.
We conclude that the recent improvements in treatment strategies in Hodgkin’s Lym-
phoma have considerably improved survival in all ages. However, age is still an impor-
tant factor indicating the need of further progress in diagnosis and treatment of older
patients.
The key aim of this thesis was to study whether serum calcium is involved in the eti-
ology and prognosis of cancers of the prostate. In our studies we did not find serum
calcium to be associated with incidence of prostate cancer, incidence of fatal prostate
cancer, prostate cancer-specific mortality, nor relative survival in prostate cancer. We
did however find a small but significant association with incidence of prostate cancer
in a stratified analysis of those men who entered the cohort at a young age, and with
a high body mass index. In a descriptive analysis of the variance of serum calcium in
correlation with other factors, we found that serum calcium was significantly associ-
ated with age, season of screening and estrogen related factors.
We conclude that though we did not find any association between prediagnostic serum
calcium and prostate cancer in our study at large, our stratified analyses together with
the descriptive analysis of variance makes it plausible that the association between cal-
cium and cancer found in other studies, partly could be confounded by a mediating, if
not causative factor, involving the mechanisms of calcium homeostasis, such as; sun
exposure, vitamin D level, level of sex hormones, body constitution, or insulin levels.
Further studies of this mechanism in general, and its association with prostate cancer
risk specifically, would be of interest when further exploring the association between
cancer and calcium.
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1 Introduction
Epidemiology is the study of the causes, distribution, and control of disease in pop-ulations.A This is the definition of epidemiology, but to me epidemiology is themagnifying glass in medicine; a tool that can detect potential risks or possible ben-
eficial aspects in medicin.
Every other day a new risk factor for cancer is announced in the daily media. If it is not
cellular phones or snuff (Swedish ’snus’), it’s potato chips or ketchup. Not rarely, what is
proclaimed as a risk factor one day, is the next day declared to be a preventive factor. When
it comes to milkB studies have shown that milk is good for the bone health, and might also
prevent different diseases such as colorectal cancer,1 but studies have also shown that it
might increase the risk of other diseases such as prostate cancer.2
In epidemiology we often begin with a suspicion of an association, and wish to examine
this further. That is, a correlation between a factor and an outcome, commonly a disease.
My thesis consists of four articles that all look at cancer from an epidemiological point of
view.
The heart of this thesis is the potential association between serum calcium and prostate
cancer, both incidence and survival. In addition to this we wanted to study temporal trends
in survival in Hodgkin’s disease. I will explain why we thought these associations would
be interesting to study, and also explain how and why we used the epidemiological and sta-
tistical methods that we did. To do so, I will start by presenting some clinical background
of the different variables in these studies.
ADefinition by the American Heritage Dictionary of the English language
BNot only milk, but dairy products in general
1

2 Background
Contents
2.1 Calcium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
2.2 Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
2.3 Other variables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
2.4 Background of associations . . . . . . . . . . . . . . . . . . . . . . . 8
2.5 Aim . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
2.1 Calcium
Calcium is a chemical element and an essential mineral for all mammals. Calcium can be
found in e.g. green vegetables, nuts, and beans, but our main dietary source of calcium
is dairy products such as milk and cheese. In the body, calcium is primarily found in the
skeleton, but it is also important for cellular function, nerve signaling, muscular function,
and blood coagulation.
Dietary calcium
Several epidemiological studies have found an association between dietary intake of cal-
cium and disease, both positive and negative associations. However, when looking at the
dietary intake of calcium one will automatically mainly study the intake of dairy products,
seeing as this is the main source of calcium in our diet. However, dairy products also
contain other components than calcium, which possibly could be an intermediar in the as-
sociation between dairy products and disease. Other factors associated with dairy product
intakemay have a confounding effect,A e.g. lactose intolerance. Though studies have found
lactose intolerance to be associated with disease, it is difficult to know if this is a result of
genetic co-variation, diet and/or ethnicity, seeing as lactose intolerance is more prevalent
in e.g. the Mediterranean and Asian countries.
AFor more information, please see page 15
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Calcium homeostasis
Since the calcium balance is so important for the body, it is controlled by a complex and
very strict system. The body can regulate the intestinal uptake, and also release calcium
from the skeleton through temporary degradation of bone. The bone mass in the body is
constantly undergoing degradation and regeneration in a process called bone turnover. This
system, also known as the calcium homeostasis, is why the level of calcium in the blood is
believed to be more or less unaffected by the dietary intake of calcium.
Serum calcium
Even though the association between dietary calcium and the blood level of calcium is
disputed, studies have shown a possible association between serum calcium level and con-
sequent disease, such as breast cancer.3
Free or ionized calcium In order to estimate the amount of calcium in the blood, one
can measure the amount in the serum. Either you analyze total calcium, or you measure
the level of free, unbound calcium, i.e. ionized calcium (Ca2+). The level of total calcium
can be misleading in individuals with an anomaly in the amount of calcium binding protein
due to other malignancies. The analysis measuring ionized calcium was less common in
the 70-ies why old cohorts seldom have information on Ca2+-levels. Ionized calcium is
considered the most accurate and/or relevant measure of calcium, but, total calcium is gen-
erally considered a fair estimate of serum calcium in healthy men.4 It is however, possible
to calculate the free calcium level from the total calcium level based on the concentration
of the protein albumin, since approximately 40 percent of calcium in blood is bound to this
protein. In article III we have calculated an estimated level of free calcium in those with
data on serum albumin, using the formula:5
Corrected calcium (mmol/L) = Total Calcium (mmol/L) + 0.02 [40 (g/L) - albumin (g/L)]
where 40 is an average amount of serum albumin in g/L
Vitamin D
Parathyroid hormone (PTH) is a
hormone produced in the parathyroid
gland, partly responsible for the release
of calcium in the blood, both by increas-
ing absorption in the intestine as well as
controlling bone resorption. PTH has
been found to be associated with can-
cers such as breast cancer.
Vitamin D is a group of fat-soluble steroids
who, together with Paratyhroid Hormone, is
involved in maintaining a balance between
calcium and phosphates in the blood. It exists
mainly in two forms; D2 (ergocalciferol) and
D3 (cholecalciferol). Vitamin D2 is mainly
attained through dietary intake of vegetables.
Vitamin D3 is partly attained through inges-
tion of dietary products like fish and nuts, but
most part is attained through the production in skin at exposure to ultraviolet B light from
the sun. The blood level of vitamin D therefore, in general, tends to vary with season.
Elderly or dark skin is known to produce lower amounts of vitamin D. Vitamin D3 is con-
sidered much more potent than vitamin D2. Vitamin D deficiency was long considered
4
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as a rare disease showing symptomatically as Rickets or Osteomalacia, but recent studies
have shown possible associations with a number of diseases, e.g. depression and cancer.6
It is possible that some of the diseases known to be more prevalent at higher latitudes, and
among e.g. African Americans are a result of a consequently low level of vitamin D due
to skin color in combination with little sun light exposure. Sun light exposure, the main
source of vitamin D, was recently found to be protective against prostate cancer7. Vitamin
D has also been found to vary significantly with season of screening, even in countries with
little seasonal difference.8
2.2 Cancer
When cells divide, they sometimes get damaged. All cells are naturally programmed to die
(i.e. go into apoptosis) in cases of error. However, some cells have a malfunction in their
control system, allowing them not only to live, but sometimes even to continue to divide.
If the body does not detect this, or is disabled to liquidate the erroneous cells, these cells
can form a tumor. Cancer is a malignant tumor; that is a tumor that not only consists of
erroneous cells, but actually continues to grow and damage surrounding tissue. Cancer is
one of the leading causes of death in the world, with almost 7.6 million fatalities in 2008
and this number is expected to grow to over 11 million in 2030.9,10 The most common
cancer worldwide is lung cancer, with more than 1.6 million new cases and almost 1.4
million fatalities in 2008.9 More than 30 percent of all cases are believed to be preventable.
Prostate cancer
Prostate-Specific Antigen
(PSA) is a protein produced
by the cells of the prostate
gland. PSA is present in
small quantities in the serum
of healthy men, but is often
elevated in the presence of
prostate disorders such as
cancer. The protein is believed
to help liquefy the semen, and
also help dissolving the cervical
mucus cap.
The prostate is a gland in men situated near the rec-
tum. The gland is responsible for producing 30 per-
cent of the seminal fluid, and is believed to help make
the semen alkaline. Prostate cancer is the fourth
most common cancer worldwide and the second most
common cancer in men.9 Many possible risk fac-
tors have been identified, such as endogenous factors
(e.g. ethnicity and genes), but also exogenous fac-
tors such as diet and latitude of residence.11 Despite
this the etiology of prostate cancer for most parts
still remains unknown. In the late 80-ies a promis-
ing method to detect prostate cancer was introduced,
namely the screening of Prostate Specific Antigen.
Through this the number of new cases diagnosed per year increased greatly, but despite
this it is unclear whether screening of prostate cancer improve survival.12
Breast cancer
Breast cancer is the second most common cancer in the world, and the most common
cancer in women. In 2008 there were more than a million new cases worldwide. The
5
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mortality is not as high as in lung cancer, but still account for almost half a million deaths
every year.9 Some identified risk factors are malfunctioning genes, such as the BRCA
genes, but most established risk factors involve the female hormone system, ranging from
hormone replacement therapy (including oral contraceptives) to obesity.B Some protective
factors include parity (number of children) and breast feeding. Other suggested factors
associated with breast cancer are serum calcium (risk factor),3 and vitamin D (protective
effect).13
Hodgkin’s Lymphoma
Non-Hodgkin lymphoma is a
group name for lymphomas not cat-
egorized as Hodgkin’s. These lym-
phomas range from almost indolent
to highly aggressive cancers.
Hodgkin’s Lymphoma (HL) is a specific can-
cer affecting the lymphocytes (white blood cells).
Since HL affects the lymphatic nodes, its effect
is systemic. In 2008 there were almost 70,000
cases reported worldwide and almost 30,000 fa-
talities.9 Thanks to advances in treatment the can-
cer is considered highly curable. However, seeing as the cancer requires a systemic thera-
peutic treatment there is a high risk of adverse effects caused by the treatment itself such
as cerebral and cardiovascular damage as well as occurrence of new cancers.
Colon cancer
During fetal development the colon grows from two different origins and is joined some-
where in the middle. This conjunction is not seen with the eye, but studies have shown
that the etiology of cancer might differ depending on which part of the colon it is situated
in. Usually colon cancer is grouped together with rectal cancer and then referred to as
colorectal cancer. Known risk factors are smoking, and alcohol, but also fatty food, and
diet low in fiber. Obesity and/or lack of exercise is also a known risk factor. One theory is
that the colon develops tumors if it absorbs mal nutrients and toxins, but another theory is
that an under stimulated colon develop cancer. Milk and dairy products have been found
to be negatively associated with colon cancer, i.e. have a protective effect.
2.3 Other variables
Body mass index (BMI)
The Body mass index is a rough measure of body constitution. It is calculated by taking
the weight in kilograms divided by the height in centimeters squared. Though not exact,
this estimate of body constitution is commonly used as a proxy for (measure of) either
fat deposit, and/or physical fitness. However, body builders and similar athletes tend to
have a BMI indicating overweight, whereas e.g. swimmers tend to have a BMI indicating
underweight, why the individual measure should be interpreted with caution. Those with
a BMI over 30 are commonly considered obese, and those with a BMI between 25 and 30
BFat tissue is known to produce estrogens
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are considered to have an overweight. Underweight is set at a BMI of either 18.5 or 20. In
my articles I have used the latter.
Socioeconomic status (SES)
Socioeconomic status, sometimes referred to as socioeconomic index, is a proxy for (mea-
sure of) living standards and economic welfare. In the cohort Malmö Preventive ProjectC
it was measured as manual or non-manual work, and not related to income or economic
situation as such. However, this may be estimated to be a fair proxy for economic status in
the 70-ies when the cohort was collected.
Age
The estimated variables and covariates in a study are very often affected by age, why almost
every study takes this into consideration in some way. However, age in epidemiological
studies can stand for different things. Either its age at entry to a cohort, age when a sample
is drawn, the age at the exposure to a risk factor or a health promoting factor, age at onset
of a disease, or a combination of several of these.
Estrogen related factors
Diseases related to biological mechanisms often tend to be affected by hormones such as
estrogen (female sex hormone). The level of estrogen is of course affected by the intake of
oral contraceptives (OC) and hormone replacement therapy (HRT), both with estrogen or
estrogen-like components. However, the hormone level is also affected by menarche (age
at first menstruation) and menopause, why the age of first and last period can summarize
a woman’s production of and exposure to her self-produced estrogens. Also how much a
woman has breastfed (a factor known to prevent e.g. breast cancer) and parity (number
of pregnancies) describe a woman’s estrogen levels. Another, less obvious factor affecting
the estrogen levels include amount of fat tissue and insulin level.
Sex
The risk of a disease sometimes differ dependant on if the individual is a man or a woman.
The strength of an association can also differ depending on this factor. The biological dif-
ference between men and women is sometimes important, especially when estrogen related
factors are of relevance. However, sometimes the difference between risk is dependent on
the different roles of women and men in society, and not the sex per se, i.e. the gender.
Marital status
Marital status is usually classified as unmarried, married, or widowed. This factor is espe-
cially relevant when the studied disease is related to psychological wellbeing, and then act
as a proxy for (marker of) social support.
CFor more information please see page 11
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Smoking
Smoking is a well known risk factor for many diseases. Not only does it leave toxins
in the lung, and damage the tissue of the lungs, but the nicotine also affect the blood
system and nerve system. It also puts a stress on the immune system. Depending on the
proposed affect of smoking it is sometimes measured in detail. Either the subjects state
the number of cigarettes per day during different periods of their lifes and we thereafter
calculate number of packages per year/month. However, this method is sensitive to e.g.
the honesty of the respondent. Another measure is a blood sample where the nicotine
derivates and other components are measured. This is not sensitive to self estimation of
number of cigarettes, and is also not sensitive to variations in how much smoke a study
participant absorbs from each cigarette. However, the measurement generally only reflects
the status at the time when the blood sample is drawn. If the exact amount of smoke
is less important one can categorize the variable e.g. as never/ever smoker, or as non-
smoker, current smoker and former smoker. This is a rough estimate of amount of cigarette
components an individual has absorbed, and does not take into consideration that potential
difference between someone who used to smoke in their young adulthood but never since,
someone who has smoked for 35 years and just stopped, and someone who started smoking
just a year ago.
Alcohol consumption
Alcohol is a factor known to be associated with different diseases in different ways. Some
studies have seen that alcohol increase the risk of disease as it is a toxin. Other studies
have seen positive effects of alcohol. It is possible that the source of alcohol is relevant,
since some studies have found a beneficial effect of e.g. a glass of red wine. It is not
clear if this association is a result of the alcohol in it-self, other components in the wine,
the psycological effect on the mind, or simply a proxy for a specific lifestyle and/or a
high living standard. Seeing as heavy alcohol consumption can be shameful to admit, and
therefore difficult to assess through a simple question, one can use different types of sys-
tematic general questions. One of these systems are the Michigan Alcoholism Screening
Test (MAST)14 and the Malmö modified MAST (Mm-MAST)15 with specially constructed
questions including attitudes towards alcohol. One of the questions included in the Mm-
MAST is e.g. Do you drink a couple of drinks (or beers) a day to relax?. These questions
are then graded according to a set system and the result is interpreted as an estimate of
general alcohol consumption.
2.4 Background of associations
Serum calcium and prostate cancer
Studies have shown that dairy products might be associated with an increased risk of
prostate cancer, and some have shown that there may be an association between dietary
calcium intake and risk of prostate cancer16–21. Giovannucci et al hypothesized that a
8
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high intake of calcium causes cancer by forcing the body to lower the levels of the tumor
suppressing hormone vitamin D (1,25(OH)2D) in order to prevent hypercalcemia.22
Studies have still not been able to determine an association between high calcium in-
take and low levels of vitamin D. Even if dietary calcium affects vitamin D levels, this
mechanism does not have to involve a pathway affecting the measurable amounts of serum
calcium seeing as the serum calcium is very tightly regulated by the calcium homeostasis
mechanism.23
Not many studies have examined the association between serum calcium and risk of
prostate cancer, but in 2008 Skinner et al found indications of a (non-significant) positive
association between serum calcium and prostate cancer in an American cohort.24 They also
saw an association between serum calcium and incidence of fatal prostate cancer, i.e., the
incidence of prostate cancers that caused death.24 This finding of an association with fatal
prostate cancer was later supported by an additional study where they speculate that serum
calcium is implicated in the etiology of only aggressive prostate cancer, and that previous
studies showing little or no association between serum calcium and prostate cancer, was
diluted by the inclusion of incident cases of indolent prostate cancer.25
Long-term survival in Hodgkin’s Lymphoma
The treatment routines in patients with Hodgkin’s Lymphoma has undergone great im-
provements and now include; more accurate radiotherapy, effective combinations of chemo-
therapy, immunotherapy, improved staging procedures and important developments in sup-
portive measures for myelosuppression, infectious and other complications. Hodgkin’s
Lymphoma has become a highly curable disease, especially for those diagnosed with an
early-stage disease. However, despite major advances over the past decades in the treat-
ment of patients with Hodgkin’s Lymphoma, the survival is affected by secondary com-
plications such as; infections, primary cancers at other sites, and cardiovascular and cere-
brovascular disease.
2.5 Aim
The purpose of this thesis is to improve human health by enabling further prevention and
more effective treatment of cancer through knowledge gained from four specific epidemio-
logical studies of cancer incidence and survival. Specifically, we will study whether serum
calcium is involved in the etiology of cancers of the prostate, and the association between
pre-diagnostic levels of serum calcium and survival of men diagnosed with prostate can-
cer. An additional specific aim is to evaluate effectiveness of treatment through studying
temporal trends in survival of patients diagnosed with Hodgkin’s lymphoma,
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3.1 Study populations
Malmö Preventive Project
In paper I-III, as well as in the the supplementary analysis of variance of serum calcium,
in Chapter 8, we have looked at an unusually large cohort called the Malmö Preventive
Project (MPP) (in Swedish called Malmö Förebyggande Medicin). Malmö is the third
largest city in Sweden with almost 280.000 residents, and is situated in the south. The
Malmö Preventive Project was started in 1974 in Malmö and invited selected birth-year
cohorts born in Malmö between the years 1920 and 1945. In 1984 the study expanded to
also include the women of selected birth-year cohorts between the years 1926 and 1949.
More than 33.000 men and women participated, resulting in a participation rate of more
than 70 percent. In paper I we study the 10.902 women of the cohort, and in paper II and
III, as well as the supplementary analysis in Chapter 8, we study the 22.444 men of the
cohort.
The original purpose of the cohort study was to evaluate general health with a spe-
cial focus on cardiovascular disease, and the participants were given a health examination,
asked to fill in a questionnaire on lifestyle factors etc, and also informed about the impor-
tance of healthy eating and regular exercise.26
Cases with Hodgkin’s Lymphoma In paper IV the study population was all those diag-
nosed with Hodgkin’s Lymphoma in Sweden between 1973 and 2005, i.e. 6,136 men and
women. This data was retrieved from the National Cancer Registry. We thereafter com-
pared the survival in those diagnosed during four different time-periods, between which
the treatment routines had progressed in order to reduce treatment-related morbidity.
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3.2 Variables
Prostate cancer
In paper II the outcome is incidence of prostate cancer. In December 2006, 1.539 of the
men had been diagnosed with prostate cancer. Cases were identified by record linkage
with the nationwide Swedish Cancer Registry and the Southern Swedish Regional Cancer
Register.
Fatal Prostate Cancer
In paper III, parts of the study have incidence of fatal prostate cancer as the outcome,
measured as prostate cancer diagnosis that later was followed by prostate cancer related
death. In December 2008 the number of prostate cancer diagnoses had increased to 1.753,
and out of these 270 where considered fatal. In paper III we also study overall mortality
measured as excess mortality among those previously diagnosed with prostate cancer. In
this group there were 612 fatalities. Information on death, and cause of death, was obtained
through the Swedish Cause of Death Registry.
Hodgkin’s Lymphoma In paper IV we studied the overall mortality in all those diag-
nosed with Hodgkin’s Lymphoma in Sweden between 1973 and 2005.Data was retrieved
from the National Cancer Registry. The outcome was excess mortality compared to the
Swedish population in general.
Serum Calcium
In paper I-III we study serum calcium measured continuously over a period of almost 15
years. During this time the type of instrument routinely used at the department of clinical
chemistry was exchanged several times. A phenomenon common in laboratory analyses
are drift, i.e. the analysis instrument tend to get out of tune, little by little with each
analysis or day that passes. This is easily dealt with by re-calibrating the instrument at
intervals using e.g. a reference sample. Some of the instruments used in the analysis
of serum calcium in our study had quite large variation, which could be a consequence
of infrequent calibration. However, it also turned out that the baseline measures of the
different instruments differed, and no data on reference sample was available. This meant
that the mean serum calcium levels before 1980 is different than that of those analyzed
after 1980. Similar to the problem with drift, this would not present a problem unless
the proportion of cases and non-cases differed between these time periods. However, the
subjects were invited to the cohort by birth-year, and seeing as prostate cancer is a disease
highly related to age, this led to a difference between the periods, not only in age, but also
in incidence of prostate cancer.
The Categorization of Serum Calcium In paper I and II we categorized the variable
serum calcium by quartiles. Per definition, quartiles are all subjects sorted from lowest to
highest, and then divided into four evenly large groups. However, seeing as the mean of the
12
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serum calcium differed between instruments, a simple quartilation could not be performed.
Instead of stratifying the following analyses on period of serum calcium measurement, we
corrected for the measurement interval by making two separate quartile definitions; one
for samples analyzed before October 1980 (71.7 percent of all subjects), and one for those
analyzed after October 1980. The two subsets of the data were thus categorized from 1 to
4 according so that each individual’s serum calcium was valued in relation to the others
in the same subset. The variable for each subset was then concatenated and treated as
one variable of serum calcium. This enabled us to look at the association between higher
and lower serum calcium, not affected by the variation between periods of analysis. The
numerical value for each of the four quartile groups was 1, 2, 3 and 4 respectively.
When several subjects has the same value as a cut-off value between quartiles, the
group-size can differ somewhat. As seen in the tables in paper II and III, the difference
in group-size between the quartiles is prominent. This is caused by the low number of
unique values in the original variable. Instead of randomly assigning the individuals with
the cut-off value to either the quartile in question, or the quartile beneath this, we chose to
continue with uneven groups to prevent risks of miss-classification.
In paper III, where we study the association between serum calcium and mortality,
some of the analyses are performed on the full cohort and other parts only on those with
prostate cancer diagnosis. We thus did one quartile categorization for the full cohort, and
one for only the prostate cancer cases in order to prevent the risk that a weak association
could disappear in the graininess of the data.
Albumin corrected calcium The MPP cohort also included level of serum albumin level
(in g/L) for 76 percent of the men in the cohort (n=17,096 out of 22,439 men), and for 83
percent of those with a prostate cancer diagnosis (n=1,457 out of 1,755). This measure
was used in order to calculate the level of free calcium using the formula below.5
Corrected calcium (mmol/L) = Total Calcium (mmol/L) + 0.02 [40 (g/L) - albumin (g/L)]
where 40 is an average amount of serum albumin in g/L
Other variables
The data from the Malmö Preventive project cohort also include the variables: Smoking
status (categorized as never, current and former), and alcohol consumption (categorized
as low, medium and high, derived from a value according to the Mm-MAST systemA), both
from the questionnaire on life-style parameters. Body Mass Index, calculated from height
and weight measured by a nurse at baseline examination at entry to the study. Season of
screening, i.e. time of baseline examination, categorized as winter, spring, summer and
fall. Socioeconomic index or status, and marital status, retrieved from the 1980 Swedish
population and housing census.27
AFor more information, please see page 8
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4.1 Directed Acyclic Graphs (DAG)
When discussing epidemiological studies we often start with a suspected association be-
tween two variables, one is often a risk factor, referred to as the exposure, and the other
is often a disease, referred to as the outcome. We also commonly have other co-varying
factors we may or may not be able to include in the analysis. Sometimes these covariates
are very important and must be controlled for in the analysis, but this may be difficult to
tell from start.
In order to facilitate the decision on what variables to stratify on, adjust for, condition
on and in other ways control for, and also to elucidate what methods to apply in doing so,
it is possible to use some type of graphical diagram such as a Directed Acyclic Graph (see
figure 4.1). This is a visual aid, and though it is far more complex than my explanation
here, I will use it as a mean to visualize parts of the projects included in this thesis.
The outcome we wish to study is commonly denoted (d) for disease and is the com-
monly the illness we wish to find the source of. The exposure is the risk factor (or health
promoting factor) we wish to study, and is commonly denoted (e) for exposure. In a DAG
there are also other factors or variables potentially associated with the exposure and/or
the outcome. Although some of these covariates, such as (a), may be irrelevant for the as-
sociation at focus, some of these should (if possible) be adjusted for in the analysis, either
by restriction, matching or by including them in the statistical model. One of the factors in
this DAG is believed to partly cause the exposure (e), but also cause the outcome (d). Such
a factor is called a confounder and is denoted (c). It is very important to adjust for such
variables in the analyses, since they otherwise can cause false associations, or block parts
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factor  (a)
factor  (b)
factor  (a)
exposure outcome
factor  (c)
Figure 4.1. Example of a DAG
of a true association. However, sometimes the confounding effect in it-self is of interest,
such as e.g. sex and/or body mass index in paper II. In the DAG (figure 4.1) we also have
a factor, (b), which is caused by the exposure (e), and is thereafter partly causing the out-
come (d). We call this an intermediar, as it lie in the causal pathway between (e) and (d).
If we wish to study only the isolated association between the exposure and the outcome,
not accounting for the causal effect that go through the intermediar, we must adjust for this
variable in the analyses. However, if we wish to get an estimate of the full association be-
tween the exposure and the outcome, including the part of the association that goes through
the intermediar, we must not adjust for this variable! There are also variables related to the
exposure and the outcome in a manner that makes them important not to adjust for. One
example is a collider, i.e a variable believed to be caused by the exposure as well as the
outcome. Adjustment for a collider risk creating a false association, or wipe out (parts of)
a true association.
Causality Although a DAG contains arrows with a distinct direction, epidemiology with
its statistical methods, can only show an association, and not causality. This means that we
can never prove with epidemiology the direction of an association, and not truly know that
there are no forgotten confounders.
4.2 Analysis of variance
In paper I and in the supplementary analysis of serum calcium variance in men, in Chapter
8, we wanted to study the association between different lifestyle factors and the level of
serum calcium. We compared means between different subgroups of the data by perform-
ing one-way ANOVA’s complemented with Bonferroni corrected tests.
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ANOVA
If we wish to study the variance between two groups, we can compare the means by doing a
t-test. However, if there are several groups, we could do an ANOVA (Analysis Of Variance)
where we compare the variance in each group with the variance from the sample means. If
a group variable is significant in an ANOVA, we may try and figure out more specifically
which of the groups that is responsible for the difference. However, performing multiple
t-tests will always risk presenting false positive correlations (i.e. type I error). To try and
adjust for this one can do a Bonferroni correction.
Bonferroni correction Instead of comparing each p-value to the chosen significance
level (α), one can chose to do a Bonferroni adjusted test, i.e. compare the p-value for
each null hypothesis to a value corrected for multiple-testing: α/n (where n is the number
of tests/hypotheses one has tested for). The reason for doing a Bonferroni correction of the
p-values is to avoid finding false positive associations due to chance.A
Logistic regression
Even though ANOVA is a simple and robust analysis, it does not take into consideration
variance that is correlated to several covariates at the same time. In the analyses of vari-
ance of serum calcium (paper I and supplementary analysis in Chapter 8), the association
between age and serum calcium was prominent. Many of the other factors in the analysis
could very well be covariates to age, why multiple adjustments could be of relevance. In
order to adjust for other variables it is possible to perform a logistic regression analysis,
with the dependant variable (the exposure) transformed to a dichotomous variable. We
therefore transformed the exposure variable (serum calcium) to a dichotomous variable,
where an individual with serum calcium above the means was given the value 1 and the
other where given the value 0. The odds of having a value above the means were then
calculated for each subgroup and compared to a reference group. In the supplementary
analysis of variance, chapter 8, we used the group with the lowest value as reference. The
choice of reference group in logistic analyses does not alter the association as such, but
merely the numerical output. The choice of reference group is therefore simply a reflec-
tion of what the authors believe is the best when it comes to interpretation of the odds
ratios.
4.3 Survival analysis
Cox proportional hazard regression
Cox regression (or Proportional hazard regression) is a survival analysis where we calculate
the probability of events per time-at-risk and compare these for different subgroups of an
exposure in relation to a reference group.
ABonferroni correct for type I errors, but at the cost of an increase in type II errors. If it is important not to
miss potential associations one can do a Bonferroni-Holm test, where you do a, less extreme, step-wise correction
of p-values
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In paper II we looked at the difference in risk of being diagnosed with prostate cancer
in four groups of serum calcium, i.e. we calculated the hazard of cancer for each cal-
cium quartile and estimated the hazard ratios (HR),with the lowest quartile as reference
group. The time-at-risk was calculated from baseline examination until date of diagnosis
(or death/end of follow-up).
In paper III we estimated the hazard ratios for incidence of prostate cancer later followed
by death per calcium quartile with time-at-risk measured from baseline examination until
date of diagnosis. In paper III we also calculated the hazard ratios for prostate cancer
specific death per calcium quartile. We did this in two ways; first for the full cohort with
time-at-risk measured from baseline examination until date of death (or end of follow-
up), and secondly in only those with a previous prostate cancer diagnosis with time-at-risk
measured from date of diagnosis until date of death (or end of follow-up). The timescale
was time since entry (or time-in-study) for all Cox analyses in this thesis, adjusted for age
at entry.
Relative survival
Cause-specific mortality relies on the accurate classification of cause-of-death. In population-
based studies of cancer patient survival it is often more relevant to study excess mortality,
i.e. the difference between all-cause mortality, and the mortality that would have been ex-
pected if the participants had not been diagnosed with cancer.28 Expected mortality can
be estimated from population life-tables, commonly stratified by age, sex, and calendar
period. Excess mortality provides a measure of mortality associated with a diagnosis of
cancer regardless of whether the excess mortality is directly or indirectly caused by the
cancer. The excess mortality can thereafter be modeled using Poisson regression29 and
adjusted for potential confounding factors.
In paper III we wanted to see if there was an association between serum calcium and
excess mortality among men diagnosed with prostate cancer. We therefore compared the
mortality in different strata’s of our cohort, to that seen in the Swedish population at whole.
The excess mortality was thereafter modeled using Poisson regression, adjusting for po-
tential confounding factors including age at baseline examination and age at diagnosis.
In paper IV we wanted to examine if the long-term survival in patients diagnosed with
Hodgkin’s Lymphoma had improved with the changes in treatment routines. We therefore
compared the excess mortality in different age groups and different periods of time. By
restricting the time-to-event in the Poisson regression model we could study the association
both at 1-, 5- and 10-year survival.
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4.4 Stratified analysis
In paper II we could see evidence of a potential interacting effect of body mass index and
age on the association between serum calcium and incidence of prostate cancer. We chose
to perform a stratified analysis, by dividing the cohort into four subsets of the data and then
analyzing each strata with Cox regression analysis. We also adjusted for age at baseline as
a continuous variable within each Cox model.
4.5 Analysis of effect of missingness
In epidemiological studies we are sometimes presented with missing data. Sometimes the
amount of data affected by missingness is worryingly large. This is especially prominent
in multivariate analyses with missing data in many different variables in several different
groups. One could then create a complete data by coding the missingness in the individuals
with missing data.
In paper II we chose to explore the effect of the missingness by performing several analy-
ses. First we looked at only subjects with complete information on all covariates. Secondly
we modeled the missing values as a separate category, i.e. the missing indicator method.
Thirdly, and finally, we wanted to see if imputing extreme values would lead to a difference
in association between serum calcium and prostate cancer incidence. The variables with
substantial amount of missingness were alcohol status and socioeconomic index (SEI). We
imputed extreme values generating four models; Alcohol imputed as low consumer and
SEI imputed as manual worker, alcohol as low consumer and SEI as non-manual worker,
alcohol as high consumer and SEI as manual worker, and alcohol as high consumer and
SEI as non-manual worker. All these models were adjusted for age at entry, smoking sta-
tus, marital status and BMI with missing as separate categories. Neither of these models
differed significantly from each other, why we chose to continue with missing categorized
as a separate category.
In paper I we did not perform any analyses sensitive to the value of the variable groups,
and thus used the missing indicator method, but in paper III we chose not to replace the
missing values, i.e. complete case analysis.
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5.1 Paper I and Variance analysis of serum calcium
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Figure 5.1. DAG of the association between serum calcium and breast cancer
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Background
The association between serum calcium (s-Ca) and cancer (of the breast) can schemati-
cally be described as in figure 5.1. The association between reproductive factors and risk
of breast cancer, (a), has since long been well established, and there was studies showing
an association between vitamin D and/or PTH and breast cancer, (b).30,31 In 2007 Almquist
et al showed a possible association between prediagnostic serum calcium and risk of breast
cancer among the women in the Malmö Preventive Project, (c).3 Seeing as both reproduc-
tive factors, (d),32–35 and lifestyle factors, (e),36 had been associated with serum calcium,
we wanted to further explore the potential determinants of serum calcium in women in
the Malmö cohort. This study also included screening season, a factor believed to affect
vitamin D, (f).37 We also wanted to study the same covariates (apart form the reproductive
factors) among the men of the Malmö Cohort, in a supplemented analysis of variance (see
Chapter 8 on page 43). This study also included the additional variables of socioeconomic
status and marital status.
Aim
”The aim of our study was to examine serum calcium concentrations in
relation to reproductive history, selected lifestyle factors and screening season
in a large population-based cohort study comprising 8,114 women.”
Additional aim for the supplementary analysis: ”The aim of our study was
to examine serum calcium concentrations in relation to selected lifestyle fac-
tors and screening season in a large population-based cohort study comprising
16.882 men.”
Material
The study population was men and women from the cohort the Malmö Preventive projectA.
All participants had their serum levels of calcium measured, as well as height and weight,
and the screening season was also registered. They were asked to fill out a question-
naire on life-style factors; such as smoking and alcohol consumption, and reproductive
factors; such as hormone-replacement therapy and age of menopausal status (when ap-
plicable). Prevalence of cancer was collected from national registries, and so was data
on Socioeconomic index as well as marital status for the men. The outcome was serum
calciumB level as a continuous variable. The exposure, i.e. the potential co-varying fac-
tors were ; age at screening, body mass index at entry to cohort, smoking status, alcohol
consumption, season of screening, and prevalent cancer.C In the women we also studied
age at menarche, menopausal status, number of children, and use of oral contraceptives
or hormone-replacement therapy.D. In the men we also studied socio economic index and
AFor more information, please see page 11
BFor more information, please see page 4
CFor more information, please see Section 2.3
DFor more information, please see page 7
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Figure 5.2. DAG for paper I
marital status. Since any of these variables could co-vary with each other, all were potential
confounders for each individual association.
Methods
Missing values were categorized as a separate category.E Differences in mean calcium
concentrations between different categories of the studied factors were studied using ANOVA
followed by a Bonferroni corrected test.F In the preparatory work before the supplemen-
tary analysis of serum calcium variance in men (Chapter 8), the mean was found to be
notably different for the men analyzed before 1980, and those analyzed after. In order to
conduct an ANOVA to compare the variance in the men, with that found in the women in
paper I, we chose to conduct the ANOVA analysis only on those analyzed before 1980.
Odds of having a serum calcium above means was calculated using logistic regression in
an unadjusted model as well as adjusted models.G
Results
We found indications of an association between serum calcium and age, as well as a strong
association between serum calcium and season in which the serum sample is drawn. In
men there seem to be higher levels of serum calcium for those screened in springtime, and
EFor more information, please see page 19
FFor more information, please see page 45
GFor more information, please see page 46
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lower levels for those screened during fall. Among the women however, there seem to be
higher levels in those screened both in spring, and in autumn.
Estrogen related factors, such as oral contraceptive use and hormone-replacement
therapy was both found to be associated with a lower level of serum calcium. Having
given birth to at least one child was also found to be associated with lower level of serum
calcium. Age of menarche was not found to be associated with serum calcium.
Body mass index was found to be strongly associated with serum calcium in women,
with higher levels for those with an “abnormal” BMI. This association was not found in
the men. Smoking and alcohol consumption was generally not found to be associated with
serum calcium, although there were indications of higher levels in former smokers in men,
and lower serum levels in those with missing data on alcohol consumption. Previous cancer
diagnosis was not found to be associated with serum calcium in our cohort. Socio economic
index and marital status was only studied in men, but was not found to be associated with
serum calcium.
Discussion and conclusion
In both paper I and the supplementary analysis of variance of serum calcium in men, in
Chapter 8, we see an association between age and serum calcium. In paper I we speculate
that this association may be partly explained by the difference in hormonal levels in women
between ages. This may be the case also in the men, but this result strengthen the theory
of age being an independent factor. Body Mass Index, was found to be associated with
serum calcium in women, but not the men. This we believe strengthen the theory that
the association between Body Mass Index and serum calcium is mediated by estrogen and
estrogen related factors such as PTH seeing as the hormonal mechanisms are different
between sexes. Smoking status was not found to be associated with serum calcium in
women, nor in the men, apart from a possible positive association in those said to be former
smokers. Alcohol was found to be associated with serum calcium only in the ANOVA
analysis in the women, and for those with missingness in the men. This show that there may
be a co-varying factor related to the missingness of alcohol consumption. The estrogen
related factors were, as expected, found to be negatively associated with serum calcium,
although age at menarche proved not to affect the level. Screening season has in other
studies been found not to be associated with serum calcium according to studies,37 but
in our studies we did see an association. Strangely enough the association was different
between men and women. In women both spring and fall was found to be associated
with an increased serum calcium, not following the theory of a sun related factors such as
vitamin D. However, in the men, the association differed between seasons with a higher
level during spring, and a lower level for those screened during fall. A lowered level of
serum calcium did thus correlate in time with an increased vitamin D level.
In conclusion, these studies show that all factors related to hormonal levels could have a
potentially confounding effect when studying serum calcium, if related to the outcome.
24
Cat Halthur 5.2. Paper II - serum calcium and incident of prostate cancer
5.2 Paper II - serum calcium and incident of prostate cancer
Background
Studies had suggested a possible association between high dietary intake of dairy products
and increased risk of prostate cancer (PCa). Giovannucci et al22 had speculated that the
biological pathway of this mechanism included a lowering of the levels of vitamin DH, a
hormone believed to prevent the development of cancer.
BMI
dairy products
calcium intake
s-Ca
vitamin D
Cancer
(prostate)
age
Figure 5.3. DAG of association between serum calcium and prostate cancer
Although many had studied the association between prostate cancer and dietary cal-
cium such as dairy products, as well as its association with vitamin D, none had looked at
serum calcium and subsequent incidence of prostate cancer.
Aim
”Our primary aim was to investigate the incidence of prostate cancer in
relation to the prediagnostic serum calcium levels in a prospective study of
22,391 healthy Swedish men. An additional aim was to examine whether this
association was modified by age and BMI.”
Material
The study population was all men in the cohort textitthe Malmö Preventive ProjectI. The
exclusion criterion was prevalence of cancer at entry to cohort. Seeing as the participants
HFor more information, please see page 4
IFor more information, please see page 11
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were quite young at entry to cohort, the prostate cancer in general debuted years after base-
line examination. Serum calcium had therefore been analyzed years prior most diagnosis
since all participants were healthy at the baseline examination in the 70ies.
s-Ca PCa
age BMI
other factors
Figure 5.4. DAG for paper II
The outcome was incidence of prostate cancer,J i.e. cases reported to the national can-
cer registry and/or to the local tumor register at Oncologic Center during follow-up. The
exposure was serum calciumK drawn and analyzed at the baseline examination at entry
to the cohort (beginning in the 70-ies) and then grouped into serum calcium quartiles.L
The confounders were age and Body Mass Index (BMI) at entry to cohort. There was
also information on lifestyle factors collected through a questionnaire around the time of
entry to the cohort. The variables smoking status, marital status, socioeconomic status,
and alcohol consumption had been considered by some studies as potential confounders,
and were therefore included in the fully adjusted analyses.M
Methods
In order to estimate the incidence of prostate cancer we did Cox proportional hazard re-
gression.N The timescale was time since entry to cohort (in days), but adjusted for age as a
JFor more information, please see page 5
KFor more information, please see page 3
LFor more information, please see page 12
MFor more information, please see section 2.3
NFor more information, please see page 17
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continuous variable. We also had a fully adjusted model, adjusting for BMI and aforemen-
tioned lifestyle factors.
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Figure 5.5. Diagram illustrating the four statistical models included in the sensitivity analysis
Missingness A number of study participants had a substantial amount of missing data,
especially for the variables socioeconomic index (n=1,137) and alcohol consumption (n=2,132).
In order to estimate the potential impact of this missingness we first did a standard multiple
adjusted model including only those with complete information on all covariates. Given
the large amount of lost data why we wished to categorize the missing values, why we
did an analysis using the missing indicator method. It is generally recommended not to
classify missing as a separate category when the reason for the missingness is unknown.
We therefore decided to do a sensitivity analysis where we imputed extreme values.O This
third analysis also included all subject, but here we chose to impute extreme values instead
of the missing in four different ways as seen in figure.5.5. This comparison showed no
difference in association between the models, why we chose to treat the missing data as a
separate category in the other analyses in this paper.
Interaction In order to study the three-way interaction between age, body mass index
and serum calcium on the association with prostate cancer risk we performed a stratified
analysis,P dividing the cohort into four subcohorts as seen in figure 5.6 and adjusting for
age at entry as a continuous variable within each Cox model.
Results
We did not see any indications of an association in general, but in the stratified analysis
there was a small association between serum calcium and risk of prostate cancer for those
OFor more information, please see section 4.5
PFor more information, please see page 19
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Figure 5.6. Diagram of the four models in the stratified analysis of the modifying effect of bmi and
age
with a BMI above 25 and younger than 45 years (Section B in figure 5.6). In this stratum
we found that those in the highest quartile of serum calcium had a hazard ratio of 0.63
(with the lowest serum calcium quartile as reference) with a confidence interval between
0.40 and 0.99. The difference between the quartiles was not very prominent, nor were
there any indications of a trend (e.g. lower hazard ratio for each increase in serum calcium
quartile).
Conclusion
This study does not support the hypothesis that high serum calcium level is a risk factor
for prostate cancer. On the contrary, the data imply that high prediagnostic serum levels
of calcium in young overweight men may be a marker for a decreased risk of develop-
ing prostate cancer. These results do not proclaim that there truly is an association, but
rather that the positive association found in other studies is not seen here, seeing as the
association in our stratum of “young” and “overweight” is negative with increasing serum
calcium. Another conclusion is that the potential three-way interaction effect between age,
bmi and serum calcium with prostate cancer risk may indicate that there is an unaccounted
confounder related to these, such as vitamin D, hormonal level, adiposity or similar.
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5.3 Paper III - Prostate cancer mortality . . .
Background
After submitting paper II, Skinner et al24 published a paper on serum calciums associa-
tion with incidence of prostate cancer, but also looking at incidence of fatal prostate can-
cer. They saw that the association between serum calcium and fatal prostate cancer was
stronger than that between serum calcium and incident prostate cancer. They believed this
supported the theory that there was a true association, merely diluted by indolent tumors
in the analyses not adjusted for the severity of prostate cancer.
Aim
”The purpose of this study was to further study our cohort of 22,390
healthy Swedish men to determine if serum calcium is a risk factor for fa-
tal prostate cancer or associated with poorer survival among men diagnosed
with prostate cancer.”
PCa related death
s-Ca aggressive PCa
s-Ca
Part 1
Part 2 & 3
excess mortalitys-CaPart 4
Figure 5.7. Schematics of the associations in paper III
Material
The study population was based on the men in the cohort the Malmö Preventive Project.Q
In two of our four analyses our study population was all men in the MPP cohort (excluding
those with prevalent cancer). The other two analyses looked only at those men diagnosed
with prostate cancer during the 35 years of follow-up.
In part 1 of the paper the outcome was incidence of fatal prostate cancer, measured
as prostate cancer diagnoses that later was followed by prostate cancer related death. In
part 2 and 3 the outcome was prostate cancer-specific death. In part 4 the outcome was
overall mortality measured as excess mortality. That is, mortality in comparison to the
QFor more information, please see page 11
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Swedish population in general. The exposure was serum calcium quartile, where the
quartile definitions for part 1 and 2 were for the full cohort, and the definitions for part 3
and 4 were for only the prostate cancer cases. Potential confoundersR were age at baseline
examination, body mass index, smoking status, and socioeconomic index. Seeing as we had
date of death as end point (and not date of diagnosis) in our excess mortality analysis, we
were able to adjust for the possible confounding effect of age at diagnosis. It turned out
that age of diagnosis was a strong confounder in the excess mortality analysis. Analyses in
part 3 and 4 were therefore, in addition to the variables in the models in part 1 and 2, also
adjusted for age at diagnosis, apart from the addition of period of diagnosis.
Methods
Skinner et al24,25 chose to study incidence of fatal prostate cancer, where an event was
defined as the diagnosis of prostate cancer, given that the subject later (or at the same time)
passed away (with prostate cancer specified as a cause of death). That is, the person time
was calculated from entry to cohort, until diagnosis of “death-causing”-cancer.
In our analyses we chose to study the mortality in four different ways:
Part 1; incidence of prostate cancer later followed by cause-specific death in the full co-
hort, i.e. hazard ratios for incidence of fatal prostate cancer (as Skinner et al did) through
Cox regression of association with serum calcium quartiles, in the full cohort, with time-at-
risk calculated from baseline examination until date of diagnosis (or death/end of follow-
up).
Part 2; cause specific mortality in the full cohort, i.e. hazard ratios for prostate cancer-
specific death through Cox regression of association with serum calcium quartiles, in the
full cohort, with time-at-risk calculated from baseline examination until date of death (or
end of follow-up).
Part 3; cause specific mortality in those with a prostate cancer diagnosis, i.e. hazard ratios
for prostate cancer-specific death through Cox regression of association with serum cal-
cium quartiles, for those with prostate cancer diagnosis, with time-at-risk calculated from
date of prostate cancer diagnosis until date of death (or end of follow-up).
Part 4; relative survival for those with prostate cancer diagnosis, i.e. Excess Mortality Ra-
tios through Poisson regression analysis of the excess mortality in different stratas of those
with prostate cancer diagnosis. Time-at-risk was calculated from date of prostate cancer
diagnosis until date of death (or end of follow-up).
Analyses 1 and 2 were adjusted for age at baseline, BMI, smoking, and SEI. Analyses 3
and 4 were also adjusted for age and period of diagnosis.
Results
We found no evidence of an association between prediagnostic serum levels of calcium and
mortality due to prostate cancer in either of our analyses; 1, fatal cancer incidence rate ratio
0.85, 95% CI: 0.56-1.31, 2, cause-specific mortality rate ratio (full cohort) - 1.02, 95% CI:
0.73-1.42, 3, cause-specific mortality rate ratio (among men with prostate cancer) - 1.04,
RFor more information, please see Section 2.3
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95% CI: 0.74-1.46, and 4, excess mortality rate ratio (among men with prostate cancer) -
0.98, 95% CI: 0.61-1.60, Highest vs lowest quartile.
Conclusion
In this study we did not find any evidence of prediagnostic serum calcium being a risk
factor for aggressive prostate cancer. We did not find any association with excess mortal-
ity, cause-specific mortality, nor incidence of fatal prostate cancer. This strengthens our
previous conclusion that possibly serum calcium in itself is not a risk factor for prostate
cancer.
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5.4 Paper IV – Long-term survival in Hodgkin’s Lymphoma
Background
Treatment of Hodgkin lymphoma (HL) has over the last 40 years improved patient survival
considerably, and HL is now considered highly curable. However, seeing as the cancer re-
quires a systemic therapeutic treatment there is a high risk of secondary disease caused by
the treatment itself, mainly cardiovascular disease. This tends to affect the long-term sur-
vival negatively, making it difficult to assess and evaluate any beneficial effects of changes
in treatment routines.
Aim
”Our aim was to assess trends in patient survival and long-term [and short-
term] excess mortality among all patients, regardless of clinical trial enrol-
ment, during this 33-year period starting when curative treatment principles
were well established.”
age & sex CVD
period
treatment
long-term 
mortality
Figure 5.8. DAG of the paper IV
Material
The study population was all those diagnosed with Hodgkin’s’ Lymphoma in Sweden be-
tween 1973 and 2005, i.e. 6,136 men and women. We have thereafter compared the
survival in those diagnosed during four different time-periods, between which the treat-
ment routines had progressed in order to reduce treatment-related morbidity. The outcome
was overall mortality, as seen in figure 5.8, measured in excess mortality compared to the
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Swedish population in general. The exposure was treatment routine measured as period
of diagnosis. Potential confounders were age and sex.
Methods
We assessed relative survival analyses, i.e. calculated Excess Mortality Ratios through
Poisson regression analysis of the excess mortality in different strata’s of age and period
of diagnosis. We thus compared the excess mortality in different age groups and different
periods of time (by sex). By restricting the time-to-event in the Poisson regression model
we could study the association both at 1-, 5- and 10-year survival, i.e. time-at-risk was
calculated from date of Hodgkin’s Lymphoma diagnosis and for 1, 5 and 10 years following
this.
Survival in Hodgkin lymphoma 
22
Figure 3c. Estimates of ten-year relative survival among HL patients in Sweden, 
stratified by age category and calendar period of diagnosis. 
 Calender Period 
 1973-1980 1981-1988 1989-1996 1997-2005 
Age category RSR 95% CI RSR 95% CI RSR 95% CI RSR 95% CI 
0-18 0.79 (0.70 to 0.86) 0.91 (0.84 to 0.95) 0.92 (0.86 to 0.95) 0.95 (0.90 to 0.97) 
19-35 0.73 (0.68 to 0.77) 0.83 (0.79 to 0.87) 0.90 (0.87 to 0.93) 0.95 (0.92 to 0.97) 
36-50 0.58 (0.51 to 0.63) 0.72 (0.65 to 0.77) 0.85 (0.79 to 0.89) 0.92 (0.85 to 0.97) 
51-65 0.33 (0.28 to 0.38) 0.49 (0.42 to 0.56) 0.58 (0.50 to 0.66) 0.80 (0.72 to 0.87) 
66-80 0.16 (0.12 to 0.21) 0.23 (0.18 to 0.30) 0.23 (0.17 to 0.31) 0.51 (0.28 to 0.75) 
     
Figure 5.9. One of the findings in paper IV: 10-year survival in Hodgkin’s Lymphoma
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Results
Relative survival had improved for all age groups, especially for those aged 51-65 years
(From RSR 0.58 to 0.80 in the last period, as seen in figure 5.9). The groups aged 0-18,
19-35 had very little excess mortality after 5-years, and also the group aged 36-50 had
in the last period reached the high levels of 5-year survival as the younger. Though the
10-year survival had improved greatly, survival is still low in the older age groups.
Conclusion
We conclude that the recent improvements in treatment strategies in Hodgkin’s Lymphoma
has considerably improved survival in all ages. However, age is still an important factor
indicating the need of further progress in diagnosis and treatment of especially older pa-
tients.
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6.1 Calcium and prostate cancer
BMI
dairy products
calcium intake
s-Ca
vitamin D
Cancer
(prostate)
age
Figure 6.1. Simplified DAG of the association between serum calcium (s-Ca) and Cancer (of the
prostate)
The main purpose of this thesis was to study whether serum calcium is involved in the
etiology of cancer of the prostate. Many studies had suggest that a high intake of dietary
calcium, such as dairy products, could increase the risk of prostate cancer.16,18–21 In 1998
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Giovannucci et al22 presented the hypothesis that a high intake of calcium causes cancer
by forcing the body to lower the levels of the tumor suppressing hormone vitamin D3 in
order to prevent hypercalcemia. This could very well be true, seeing as there e.g. is a dif-
ference in prostate cancer incidence and survival between African Americans and White
Americans38. Studies had also shown that not only colon and skin, but also breast and
prostate tissue have the enzymatic machinery to produce the active form of Vitamin D3,
also known as calcitriol (1,25(OH)2D).39
In paper II we wished to explore the association between calcium and cancer, by study-
ing prediagnostic serum calcium and the association with prostate cancer. Seeing as serum
calcium is believed to be tightly regulated it did not have an apparent active role in the pro-
posed pathway between dietary calcium and cancer. However, by looking at a very large
cohort, we believed we would be able to detect even small variations in serum calcium
between those who developed prostate cancer, and those who didn’t. Or more precise, we
believed we could see a difference in prostate cancer incidence between groups of different
serum calcium level.
We didn’t. Well, actually we could see a small association in a subgroup of young
and overweight men, but this association was negative, i.e. showing a possible protective
effect of high serum calcium, i.e. the opposite of what was anticipated. This association
was weak, and does not imply that there is a true negative association. It does however
suggest that, seeing as the positive association found in other studies is not seen here, the
association between dietary calcium intake and prostate cancer is less likely to act through
an effect of a measurable increase in the amount of serum calcium, but rather through other
factors associated with diet, such as e.g. other components in dairy products.40
Serum calcium could be a marker for the dietary intake of calcium, and it is possible
that the source of calcium in the diet of Swedish men differ from other study populations
in regard to e.g. consumption of sour cream and milk. In 2010 Newmark et al proposed
that the association between dairy products and prostate cancer is not due to the calcium,
but instead a result of the high content of phosphate.41 This does well correlate with our
results, that serum calcium in itself is not associated with prostate cancer. It could instead
act as a possible marker for e.g. high dietary intake of phosphate through dairy products.
However, during the time when our first paper on prostate cancer and calcium was about
to be published, another group of researchers studied the same association (serum calcium
and prostate cancer) in an American cohort.24 They, as opposed to us, did find a positive as-
sociation in the full cohort. They also showed that this association may be more prominent
in those with an aggressive prostate cancer.24,25
In the 70-ies researchers discovered that at presence of prostate infection and prostate
cancer, one could see elevated serum levels of a protein later denoted PSA, prostate-
specific antigen.42 PSA is (amongst other things) an agent in semen, optimizing fertil-
ization. Serum analysis of level of PSA is routinely used as an aid in early detection of
prostate abnormalities such as prostate cancer. Although PSA is not part of any national
screening program in Sweden, it is offered free of charge in national health care for anyone
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requesting it. However, though sensitive for prostate cancer, it is not significant, why not
all of the men with elevated PSA have prostate cancer. There are also many cases where
men with PSA elevation at biopsy are found to have prostate cancer, but at such an early
stage, or even pre-stage cancer, that the risk of them ever developing severe cancer is highly
unlikely. Skinner et al suggested that PSA screening risked introducing misclassification
by increasing the diagnoses of indolent cancer, and thus risk diluting a true association,
which would explain the significant association they found between serum calcium and
incidence of fatal prostate cancer.24,25
In paper III we therefore wanted to explore the possibility of an association between
serum calcium and aggressive prostate cancer. We did this both by looking at the associa-
tion between serum calcium and incidence of fatal prostate cancer, but also looking at the
association between serum calcium and the risk of prostate cancer specific death. We also
figured that if there was an association between serum calcium and the aggressiveness of a
tumor, we should be able to, in the men who developed prostate cancer, see a difference in
over-all excess mortality between groups with different level of serum calcium.
We didn’t. Not even in our body-mass-index-and-age-stratified analyses could we see
any signs of an association, neither positive nor negative. This is suggesting that either the
mediating effect of body mass index and age on the association between serum calcium
and prostate cancer was a finding by chance, or possibly prediagnostic serum calcium does
not predict prognosis in prostate cancer, but merely the incidence of diagnosis of indolent
tumors.
One of the critiques against our first prostate cancer study (paper II) was that we looked
at total calcium, and not ionized calcium. We therefore calculated the amount of free
calcium based on the level of albumin. Albumin is the protein that is believed to bind a
substantial amount of calcium in the blood. By estimating the amount of albumin-bound
calcium and subtracting that from the amount of total calcium, it is believed we get a fair
estimate of the level of free calcium in the blood.43 But nor these analyses did show an
association with prostate cancer mortality.
We also considered the possibility that, though we specifically looked at mortality
(as cause specific mortality and excess mortality among prostate cancer cases) our results
could be diluted by indolent cancers diagnosed through Prostate Specific Antigen screen-
ing.44 Seeing as we did not have information on why and how the cases were diagnosed
with prostate cancer, we separated our cohort in two subsets, one for those analyzed before
2000, and one for those analyzed after. PSA analysis is not in any screening program in
Sweden, but was introduced in the late 90-ies for anyone requesting it free of charge. We
did not see any difference in association between those diagnosed pre and post the intro-
duction of PSA test in Sweden.
Paper I explored the association between potential confounders and serum calcium in
women. In a supplementary study of serum calcium variance, in Chapter 8, I looked at the
association between potential confounders and serum calcium but in men, in case there was
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a difference in association between sexes. The results from this previously unpublished
exploratory study can be found in Chapter 8 on page 43, and include similar statistical
analyses as in paper I. In cases where the determinant variable is a continuous variable one
may prefer a general linear regression analysis. Just as in logistic regression it is easy to
include other covariates in the model as opposed to e.g. the ANOVA. Another benefit is
that in linear regression the resulting estimates are in the same unit as the determinant vari-
able and therefore sometimes more clinically interpretable. We therefore also performed a
linear regression analysis of serum calcium in men as a complement for the supplementary
analysis of variance (data not shown). This analysis confirm the same associations as the
logistic regression analysis and the Bonberroni corrected tests.
In paper I we saw a strong effect of screening season on serum calcium. We did not
adjust for screening season in paper II and paper III simply because the season of prediag-
nostic screening is not likely to predict neither the incidence of nor the survival in prostate
cancer, and thus not present a confounding effect on the association with serum calcium.
However, if the seasonal effect means that we did not estimate the serum calcium correctly
due to large variation it could introduce a misclassification bias by poor estimates of the
serum calcium quartile. A simple adjustment for screening season in the model, could
resolve parts of such a problem. However, if a true association was undetectable due to
vast variation, a screening season-stratified quartilation, much like what was applied when
dealing with the instrumental variation, could be enough to reveal a true association in a
future analysis.
In the “trend analysis” in paper II we modeled the serum calcium quartile variable as
a categorical, with the values 1 through 4 imputed. This was suboptimal, since it’s always
better if the difference between the values of two groups (the increment) better represent the
proportional change from one group to another. However, seeing as the quartilations were
done in two steps, imputing the mean value would have been misguiding. As mentioned,
we did not find a trend or any indication of an association in these analysis.
In paper II and III a potential confounder is age. Serum calcium decrease with age,
and since the incidence of prostate cancer increase with age those entering the cohort at an
older age (and who therefore have a higher prediagnostic level of serum calcium) are more
likely to become cases within the follow-up of 35 years, than those entering the study at a
very young age. Although the effect of screening age on the incidence of prostate cancer
decreases to a minimum as the cohort progress, this could lead to a false positive associa-
tion between serum calcium and prostate cancer if not adjusted for. When looking at the
survival, we also have age of diagnosis as a potential confounder. In the analyses where
incidence of prostate cancer diagnosis (followed by cause-specific death) is the outcome,
we cannot adjust for this variable. However, we did not see an association in the analyses
where we could adjust for this.
In order to be able to compare our results with those by Skinner and colleagues, we did
a cox analysis looking at diagnosis of prostate cancer later followed by death caused by
cancer. In the article we state:
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“Men stopped being at risk on 31 December 1998 but we continued to
follow the men until 31 December 2008 in order to determine whether incident
cases of prostate cancer were ‘fatal’ and avoid possible misclassification of
fatal cases as non-fatal cases due to lack of follow-up. If we did not make this
adjustment then men diagnosed with prostate cancer during later years (e.g.,
2008) would be less likely to be classified as cases of fatal prostate cancer
since they would have a considerable shorter time at risk in which the cancer
could cause their death”
However, an unadjusted analysis would not lead to a misclassification of a case, because,
in the analysis we compare the number of cases (i.e. PCa diagnoses later followed by
PCa-specific death) with non-cases. That is, those diagnosed with prostate cancer who
does not die from their cancer before end of follow-up, are considered non-cases regard-
less of whether or not we have a cut-off in 1998. This is because we do not make any
difference between a nonfatal prostate cancer and a cohort participant not diagnosed with
cancer. This adjustment does however make us lose some true cases of fatal prostate can-
cer, that is those diagnosed and diseased between 1998 and 2008. So why do we make this
adjustment? Well, there is a difference in person-time. We do not want yet not manifested
true cases to contribute person-time to the group of non-cases. This is why we chose to not
account for any person-time after 1998.
In 1996 Leifsson et al found a positive association between serum calcium and excess
mortality in the general population.45 They found that most part of this excess mortality
in those with higher serum calcium was attributable to cardiovascular disease, but almost
30 percent was believed to be attributed to other malignant disorders such as cancer. This
could strengthen the belief that serum calcium is positively associated with the severity of
prostate cancer. In paper III we compared the excess mortality between serum calcium
quartiles in men diagnosed with prostate cancer in order to assess if serum calcium is
associated with the prognosis in prostate cancer. If there is a general association between
serum calcium and mortality in our population we would not be able to adjust for this in
our relative survival analysis, and thus these analysis would be invalid. However, Leifsson
et al found serum calcium to be positively associated with mortality,45 and Skinner et al
also found it to be positively associated, but with fatality in prostate cancer.25 If either or
both these positive associations existed in our cohort, we should have at least detected an
association. This could mean that in our data, there is a positive association with prostate
cancer, but hidden by a negative association with mortality in general. Now, that is on the
contrary to what Leifsson et al found in their aforementioned study. There could also be
a true negative association with prostate cancer in our cohort, similar to what we found in
the subset in paper II, but thus hidden by a positive association with overall mortality in
the general population, in accordance with the results of Leifsson et al. However, if so,
we should have been able to see a difference in the analysis of incidence of fatal prostate
cancer in the full cohort.
A future study of interest would be to either study the association between serum cal-
39
6. Discussion Cancer and Calcium
cium and over-all mortality in the full cohort, or even in those free from cancer. If such an
analysis show an association in our cohort it would be interesting to study the difference in
mortality in those diagnosed with prostate cancer compared to those in the full cohort, and
see if this excess mortality differ between groups of serum calcium.
One explanatory hypothesis of an association between calcium and cancer involves hor-
mones. In paper I we could see that most estrogen related factors were related to serum
calcium in a sense that high estrogen levels seem to be associated with lower levels of
serum calcium. However, a high Body Mass Index was related to higher level of serum
calcium, though fat tissue is known to produce estrogen as well as leptin.46 This effect is
however known to be more distinct after menopause. The association with body mass index
was not seen in the men analyzed in the supplementary analysis of variance but estrogens
have been found to be associated also with prostate cancer.40 We could also see that there
was a difference between men and women in the association of serum calcium and season
of screening. It is not farfetched that the hormonal differences between sexes are mediat-
ing in the association between serum calcium and season and body mass index. Hormonal
levels could also explain the results in paper II where we found a potential three-way in-
teraction effect between age, BMI and serum calcium with prostate cancer. Both season
of screening, vitamin D level, body mass index, fat mass/adiposity, insulin levels and skin
color are factors correlated with each other, and many of these factors have been associated
with estrogen level, PTH level, serum calcium and risk of cancer.47,48 Further studies of
these associations in general, and their association with prostate cancer risk specifically,
could elucidate the potential association between cancer and calcium.
6.2 Temporal trends and survival in Hodgkin’s Lymphoma
This thesis also includes Paper IV, where we study the difference in short-term and long-
term survival in Hodgkin’s Lymphoma between different time periods. The reason for
this was to see if the recent changes in treatment strategies of Hodgkin’s has decreased
the amount of treatment-related morbidity and mortality. It is difficult to assess progress in
treatment of a disease where many get cured, but die from side effects from the treatment it-
self. One can look at cause-specific mortality, as we did in paper III when the outcome was
prostate cancer specific mortality, but that requires that the death registry has a reliable in-
terpretation of cause-of-death. When it comes to Hodgkin’s Lymphoma the disease-related
mortality include causes such as cardiovascular disease, primary cancer, or infection. A
correct interpretation of cause-specific death would therefore be difficult to make, which
is why we chose to study excess mortality instead. By studying the difference in excess
mortality between periods of time we could get an estimate of the temporal trends. Here
we could see that the changes in routines seem to have made a difference in long-term
survival for all age-groups, even though the excess mortality is still quite high especially
for those diagnosed at a higher age.
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One specific aim of this thesis was to evaluate effectiveness of treatment through studying
temporal trends in survival of patients diagnosed with Hodgkin’s lymphoma.
We conclude that the recent advances in treatment in, and diagnosis of, patients with
Hodgkin’s Lymphoma has considerably improved short-term, as well as long-term sur-
vival in all ages. However, age is still an important factor indicating that extra care and
caution should be put in the decision of current and future treatment strategies in and clin-
ical care of older patients.
The key aim of this thesis was to study whether serum calcium is involved in the etiol-
ogy of cancers of the prostate, and if there is an association between pre-diagnostic levels
of serum calcium and survival of men diagnosed with prostate cancer.
In our studies we did not find serum calcium to be associated with incidence of prostate
cancer, incidence of fatal prostate cancer, prostate cancer-specific mortality, nor relative
survival in prostate cancer.
We did however find a small but significant association with incidence of prostate cancer
in a stratified analysis of those men with a high body mass index, and entering the cohort
at young age. This together with the serum calcium’s strong correlation with season of
screening and estrogen related factors, makes it possible that the association between di-
etary calcium and cancer could partly be explained by a mediating, if not causative, effect
involving the mechanisms of calcium homeostasis such as; sun exposure, vitamin D level,
level of sex hormones, body constitution or insulin level.
Further studies of this mechanism in general, and its association with prostate cancer risk
specifically, would be of interest when exploring the association between cancer and cal-
cium.
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8 Supplementary analysis of variance
Determinants for Serum Calcium concentrations in men
(unpublished original work)
BACKGROUND: Several studies have examined the possible association between pre-
diagnostic serum calcium and the risk of cancer, such as breast cancer and prostate cancer.
The causal pathway is unclear and many factors are believed to affect both serum calcium
as well as cancer risk.
OUTLINE: In order to explore potential confounders’ individual association with cal-
cium, we analysed the difference in serum calcium levels between different groups in a
subset of 16,882 healthy Swedish men from the Malmö Preventive Project, started in the
70-ies.
METHODS & MATERIAL: All participants had their serum levels of calcium mea-
sured, as well as height and weight. They were also asked to fill out a questionnaire on
life-style factors such as smoking and alcohol consumption. Socioeconomic data as well
as marital status and prevalence of cancer was collected from national registries after given
consent. Variance in serum calcium was analysed in a one-way ANOVA complemented
with Bonferroni corrected tests. Odds of having a serum calcium above means was calcu-
lated using logistic regression in an unadjusted model as well as adjusted models.
RESULTS: We found a significant difference in serum levels of calcium between groups
examined at different ages (ANOVA p=0.000). Bonferroni corrected tests showed signif-
icant difference in those examined at ages 38-44 (p=0.001) compared to means of those
younger than 38. However, Odds Ratio of having serum calcium level above mean was
1.11 (95% CI: 1.01-1.22, p=0.035, crude model) for those aged 48 or older (comp. to
younger than 38), and this increased further when fully adjusted (1.42, 95% CI: 1.25-1.62,
p=0.000). We found a significant difference in means in groups screened in different sea-
sons (ANOVA p=0.000), and Bonferroni corrected tests showed significant p-values for
those examined in spring and fall (winter as reference). Logistic regression showed sig-
nificantly higher Odds Ratio for those examined in spring compared to those examined
in winter (OR 1.22, 95% CI: 1.12-1.33, p=0.000, fully adj.). The corresponding Odds
Ratios for individuals examined in fall (comp. to winter) was (0.79, 95% CI: 0.72-0.86,
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p=0.000). We did not find evidence of an association with Body Mass Index, Prevalent
cancer, Socio Economic Index nor Marriage status. We found a small but significant
association with serum calcium in smokers (ANOVA p=0.018), and Odds Ratio of 1.07
for former smokers compared to never-smokers (95% CI: 1.01-1.17, p=0.023, fully ad-
justed model). However, Bonferroni corrected p-value for this group was not significant
(p=0.173, ref. never-smokers). We found a significant Odds ratio for the alcohol consump-
tion strata for "missing data" compared to non-drinkers (OR 0.66, 95% CI: 0.57-0.75, fully
adjusted model). However, the one-way analysis of variance showed a low but not signifi-
cant p-value for ANOVA analysis of alcohol consumption (p=0.070) as well as Bonferroni
corrected p-value for those missing data (p=0.058, ref non-drinkers).
CONCLUSION: We found indications of an association between serum calcium and
age, as well as a strong association between serum calcium and season in which the serum
sample is drawn. Alcohol consumption, Body Mass Index, Smoking status, Marriage status
and Socio Economic Index was not found to be associated with serum calcium in our data.
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Table 8.1. Mean serum calcium levels in relation to life-style factors, and season
Variable No. Mean 95% CI Bonferroni t-test ANOVA
(p-value) (p-value)
Age at screening
<38 3053 2.418 2.329-2.508 (ref)
38-44 3558 2.410 2.307-2.512 0.001
45-47 6664 2.414 2.329-2.500 0.280
48 or old 3608 2.419 2.336-2.502 1.000 0.000
Body Mass Index
less than 892 2.413 2.322-2.504 (ref)
20-24 8954 2.415 2.325-2.506 1.000
25-29 5997 2.415 2.327-2.503 1.000
30 or mor 1036 2.416 2.327-2.504 1.000 0.850
Smoking status
never 5363 2.414 2.324-2.504 (ref)
ex 8583 2.417 2.326-2.508 0.173
current 2937 2.412 2.329-2.495 0.978 0.018
Alcohol consumption
Low 6775 2.417 2.329-2.504 (ref)
Medium 6632 2.415 2.325-2.506 1.000
High 1344 2.414 2.312-2.515 1.000
missing 2132 2.411 2.327-2.494 0.058 0.070
Prevalent cancer
No 6755 2.415 2.326-2.504 (ref)
Yes 128 2.425 2.312-2.539 0.191 0.191
Screening season
winter 6082 2.417 2.330-2.504 (ref)
spring 2964 2.429 2.340-2.519 0.000
summer 4203 2.415 2.326-2.504 1.000
fall 3634 2.401 2.310-2.493 0.000 0.000
Socio Economic Index
Manual wo 6923 2.416 2.328-2.505 (ref)
Non-manua 6931 2.414 2.326-2.502 1.000
Self empl 1476 2.412 2.318-2.506 0.928
Other 666 2.420 2.321-2.519 1.000
missing 887 2.415 2.323-2.507 1.000 0.206
Marriage status
unmarried 2329 2.416 2.321-2.511 (ref)
married 2458 2.415 2.328-2.503 1.000
divorced 1921 2.413 2.320-2.505 1.000
widowed 106 2.399 2.300-2.498 0.528
missing 69 2.435 2.346-2.524 0.858 0.079
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Table 8.2. Crude and adjusted odds ratios (OR) for high (>2.415 mmol/l) vs. low (<=2.415
mmol/L) serum calcium levels from multiple regression analysis, in relation to life-style factors, and
season of baseline examination
Variable Crude Age adjusted Fully adjusteda
OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value
Screening age
younger than 38 1.00 (ref) - 1.00 (ref) - 1.00 (ref) -
38-44 0.99 0.90-1.09 0.891 0.99 0.90-1.09 0.891 1.03 0.93-1.14 0.529
45-47 0.98 0.90-1.07 0.685 0.98 0.90-1.07 0.685 0.99 0.91-1.09 0.881
48 or older 1.11 1.01-1.22 0.035 1.11 1.01-1.22 0.035 1.42 1.25-1.62 0.000
Body Mass Index
less than 20 1.00 (ref) - 1.00 (ref) - 1.00 (ref) -
20-24 1.03 0.90-1.19 0.662 1.03 0.90-1.18 0.666 1.06 0.92-1.22 0.424
25-29 1.07 0.93-1.23 0.341 1.07 0.93-1.23 0.354 1.11 0.96-1.28 0.168
30 or more 1.01 0.84-1.21 0.943 1.00 0.83-1.20 0.993 1.03 0.86-1.24 0.727
Smoking status
never 1.00 (ref) - 1.00 (ref) - 1.00 (ref) -
former 1.08 1.01-1.16 0.022 1.08 1.01-1.15 0.036 1.09 1.01-1.17 0.023
current 0.97 0.88-1.06 0.482 0.96 0.87-1.05 0.367 0.96 0.87-1.05 0.373
Alcohol consumption
low 1.00 (ref) - 1.00 (ref) - 1.00 (ref) -
medium 1.01 0.94-1.08 0.81 1.02 0.95-1.09 0.613 1.02 0.95-1.09 0.596
high 0.95 0.84-1.07 0.397 0.96 0.86-1.09 0.545 0.96 0.85-1.08 0.480
missing 0.92 0.84-1.02 0.119 0.71 0.62-0.81 0.000 0.66 0.57-0.75 0.000
Prevalent cancer
no 1.00 (ref) - 1.00 (ref) - 1.00 (ref) -
yes 1.08 0.76-1.52 0.682 1.06 0.75-1.51 0.728 1.08 0.76-1.53 0.672
Screening season
winter 1.00 (ref) - 1.00 (ref) - 1.00 (ref) -
spring 1.25 1.14-1.36 0.000 1.24 1.13-1.35 0.000 1.22 1.12-1.33 0.000
summer 0.96 0.89-1.04 0.363 0.96 0.89-1.04 0.337 0.92 0.84-0.99 0.037
fall 0.83 0.76-0.90 0.000 0.82 0.76-0.89 0.000 0.79 0.72-0.86 0.000
Socio Economic Index
manual worker 1.00 (ref) - 1.00 (ref) - 1.00 (ref) -
non-manual 0.95 0.89-1.02 0.168 0.95 0.89-1.02 0.146 0.96 0.90-1.03 0.299
self employed 0.89 0.79-1.00 0.044 0.89 0.79-1.00 0.041 0.90 0.80-1.00 0.060
other 0.96 0.82-1.13 0.617 0.95 0.81-1.12 0.531 0.96 0.82-1.13 0.651
missing 0.94 0.81-1.08 0.356 0.93 0.81-1.07 0.316 0.91 0.79-1.05 0.209
Marriage status
unmarried 1.00 (ref) - 1.00 (ref) - 1.00 (ref) -
married 0.99 0.91-1.09 0.884 0.99 0.90-1.08 0.756 0.99 0.90-1.08 0.808
divorced 0.93 0.83-1.06 0.274 0.93 0.82-1.05 0.265 0.92 0.81-1.04 0.191
widowed 1.11 0.75-1.64 0.598 1.10 0.74-1.62 0.639 1.09 0.74-1.61 0.671
missing 1.28 0.79-2.07 0.312 1.29 0.80-2.09 0.293 1.31 0.80-2.14 0.281
aAdjusted for age at baseline examination (younger than 38, 38-44, 45-47, 48 or older), Body Mass Index
(less than 20, 20-24, 25-29, 30 or more ), smoking status (never, former, current), Socio Economic Index (man-
ual worker, non-manual worker, self employed, other, missing), Prevalent cancer (yes/no), Season of baseline
examination (winter, spring, summer, fall)
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